Pathstone Family Office’s Alexion Pharmaceuticals ALXN Stock Holding History

Pathstone Family Office’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-842	Closed	-$131K	–	1468
2020 Q4	$131K	Buy	842 +755	+868%	+$97K	0.01%	339
2020 Q3	$10K	Hold	87	–	–	﹤0.01%	607
2020 Q2	$10K	Sell	87 -230	-73%	-$24.4K	﹤0.01%	526
2020 Q1	$29K	Buy	317 +87	+38%	+$8.54K	﹤0.01%	379
2019 Q4	$24.9K	Hold	230	–	–	﹤0.01%	388
2019 Q3	$23K	Hold	230	–	–	﹤0.01%	379
2019 Q2	$30K	Hold	230	–	–	﹤0.01%	400
2019 Q1	$31K	Buy	+230	New	+$28.6K	﹤0.01%	373
2017 Q2	–	Sell	-12	Closed	-$1K	–	688
2017 Q1	$1K	Buy	+12	New	+$1.55K	﹤0.01%	547
2013 Q3	–	Sell	-23	Closed	-$2K	–	457
2013 Q2	$2K	Buy	+23	New	+$2.22K	﹤0.01%	346

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Family Office's ALXN Position: Q1 2021 in Review

Pathstone Family Office sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 842 shares — an estimated $131K sold.

Pathstone Family Office first reported a position in ALXN in Q2 2013 and held it in 10 quarters. The position peaked at $131K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Pathstone Family Office reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 842 Alexion Pharmaceuticals shares in Q1 2021, an estimated $131K.
Pathstone Family Office first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Pathstone Family Office's Alexion Pharmaceuticals position peaked at $131K in Q4 2020.
754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.